Aims: To evaluate the long-term safety and efficacy of tofogliflozin as an add-on treatment to insulin over 52 weeks.
be effective in terms of improving glycaemic control. 5, 6 According to American Diabetes Association guidelines, use of an adjunctive SGLT2 inhibitor along with insulin may be helpful in ameliorating glycaemic control, as well as reducing the amount of insulin needed in patients with suboptimal glycaemic control, especially in those requiring increased insulin doses. 7 To date, information regarding the long-term safety and efficacy of combination therapy with insulin and tofogliflozin for T2DM patients is limited. Thus, we conducted a 52-week, multicentre, Phase 4 study that integrated a 16-week, randomized, double-blind, placebo-controlled phase and a subsequent 36-week, open-label extension phase to assess the safety and efficacy of tofogliflozin added to insulin in patients with T2DM (J-STEP/INS). 8 The previous report showed that combination therapy of insulin and tofogliflozin demonstrated significantly greater improvement in HbA1c (−0.59%, P < .0001), FPG (−27.2 mg/dL, P < .0001) and post-prandial plasma glucose (PPG) (−65.0 mg/dL, P < .0001) at Week 16 compared to placebo. Diastolic blood pressure (−1.8 mmHg, P = .0218) and body weight (−1.34 kg, P < .0001) were also decreased in the tofogliflozin group, with statistical significances over placebo. With detailed information on results of the double-blind phase reported elsewhere, 8 this report further evaluates the long-term safety and efficacy of tofogliflozin as add-on treatment to insulin during 52 weeks.
| MATERIALS AND METHODS

| Study design
This was a 52-week, multicentre, Phase 4 study that comprised 2 phases: 1) a 16-week, randomized, double-blind, placebo-controlled phase, referred to as the double-blind phase, and 2) a subsequent 36-week open label extension phase, referred to as the extension phase, followed by 3-day follow-ups conducted from June 2014 to January 2016 (NCT02201004) ( Figure S1 ).
| Patients
Patients diagnosed with T2DM were recruited from diabetic clinics in Exclusion criteria included type 1 diabetes mellitus, unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment during the study period, history of metabolic acidosis ≤1 year prior to the screening visit, history of severe uncontrolled glycaemia, pregnancy or lactation, or the judgement by the attending investigators that participation was inappropriate based on any medical, psychological, social or geographical reasons. Further details are described elsewhere. 8 
| Procedures
After a 2-week screening period, we randomly assigned patients in a 2:1 ratio to tofogliflozin or placebo using the minimization method. Patients in the tofo-tofo group were older and had a lower proportion of BMI ≥ 30 kg/m 2 and longer duration of diabetes compared with the pla-tofo group (Table 1) . We observed no other notable differences in demographic and baseline characteristics. Mean treatment duration AE SD was 349.8 days AE56.9 in the tofo-tofo group and 247.7 days AE18.0 in the pla-tofo group. Table 2 summarizes safety results during the 52-week on-treatment period of the tofo-tofo group and the extension phase of the pla-tofo group. No deaths occurred throughout the study. In addition, we observed no major differences in occurrence of AEs during the 52-week and 36-week peeriods.
| Long-term safety
In the 52-week on-treatment period (tofo-tofo group), serious TEAEs including hypoglycaemic unconsciousness, coronary artery stenosis, spondylolisthesis and ankle fracture occurred in 4 patients (2.9%). Prolonged electrocardiogram QT, graded mild, was reported in 2 patients (1.4%). TEAEs leading to permanent treatment discontinuation were reported in 5 patients (3.6%), including genital infection, worsening of glucose control, peripheral arterial occlusive disease, cold urticarial and increased blood creatine phosphokinase. During the extension phase in the pla-tofo group, serious TEAEs occurred in 5 patients (7.4%), including gastroenteritis in 2 patients and cellulitis, cardiac failure and myocardial infarction in 1 patient each. Prolonged electrocardiogram QT, graded mild, was reported in 1 patient (1.5%).
A TEAE leading to permanent treatment discontinuation was reported in 1 patient (1.5%) with drug eruption, which was considered to be related to tofogliflozin.
Hypoglycaemia was the most common TEAE in both the tofo- high) and basal insulin, respectively. Table S1 shows the incidence rates of patients who experienced hypoglycaemia per 100 personyears for the tofo-tofo and pla-tofo groups. Overall, the insulin dose slightly decreased from baseline to Week 52 (mean change AE SE, −1.27 U AE 0.615 and −0.58 U AE 0.915 in the tofo-tofo and pla-tofo groups, respectively) ( Figure 2B ).
| Long-term efficacy
As observed with the HbA1c and FPG levels, body weight reduced after tofogliflozin add-on to insulin treatment in the tofotofo and pla-tofo groups and this reduction was maintained throughout the study. Abbreviations: BMI, body mass index; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; ITT, intention-to-treat; PPG, postprandial plasma glucose; SD, standard deviation. Patients who received tofogliflozin in both double-blind and extension phases were referred to as "tofo-tofo group", and patients who received placebo in double-blind phase and tofogliflozin in extension phase were referred to as "pla-tofo group". Data are mean AE SD unless otherwise indicated.
a As reported by the attending physician. Abbreviation: TEAE, treatment emergent adverse event. Patients who received tofogliflozin in both double-blind and extension phases were referred to as "tofo-tofo group", and patients who received placebo in double-blind phase and tofogliflozin in extension phase were referred to as "pla-tofo group". The period from the first dose of the tofogliflozin up to 7 days after the last dose of the tofogliflozin during 52 weeks was analyzed for the safety results of the tofo-tofo group. The period from the next date of Week 16 up to 7 days after the last dose of tofogliflozin was analyzed for the safety results of the pla-tofo group. Data are n (%).
a The intention-to-treat population is defined as all patients randomized and exposed to at least one dose of the tofogliflozin in the double-blind period.
b The intention-to-treat population for the open-label period was defined as subjects randomized to the pla-tofo group who completed the double-blind period and were exposed to at least one dose of the tofogliflozin in the open-label period.
c TEAEs classified as "Investigation" occurring in >2% patients in either group are summarized.
d One patient with hypoglycaemic unconsciousness did not meet the definition of severe hypoglycaemia defined in the study protocol in terms of not receiving a third person's help. As a third person's help is indispensable in a patient with hypoglycaemic unconsciousness, regardless of whether receiving actual help or not, this hypoglycaemia is categorized as severe in this paper.
e Hypoglycaemic events that were associated with typical hypoglycaemic symptoms with an accompanying plasma glucose ≤70 mg/dL (3.9 mmol/L).
f Hypoglycaemic events that were not associated with typical hypoglycaemic symptoms with an accompanying plasma glucose ≤70 mg/dL (3.9 mmol/L).
Mean change AE SE from baseline to Week 52 was −1.52 kg AE 0.207 and −2.13 kg AE 0.313 in the tofo-tofo and pla-tofo groups, respectively ( Figure 2C ).
Mean changes in HbA1c, FPG, insulin dose and body weight from baseline to Week 52 by each insulin regimen (basal-bolus, bolus, premix [low and high] and basal) are summarized in Table S2 . (Table S2 ).
In the tofo-tofo group, the proportion of patients who achieved HbA1c < 7.0% at Week 52 was 15.0%, and those who achieved HbA1c ≤ 6.5% at Week 52 was 3.6%.
| DISCUSSION
We examined long-term safety and efficacy of tofogliflozin added to insulin over 52 weeks in T2DM patients in whom glycaemic control was inadequately controlled despite insulin use. The safety profiles of tofogliflozin were generally consistent with those reported in a 16-week on-treatment period study, 8 and tofogliflozin treatment was well tolerated over the 52-week period. No death occurred during this study. Hypoglycaemia was the most common AE in the tofo-tofo Abbreviation: BP, blood pressure; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation. Patients who received tofogliflozin in both double-blind and extension phases were referred to as "tofo-tofo group", and patients who received placebo in double-blind phase and tofogliflozin in extension phase were referred to as "pla-tofo group". The analysis included data obtained from the first dose of the tofogliflozin or placebo during the whole treatment period or up to the introduction of the rescue medication, 1 day after the last dose of the tofogliflozin or placebo, whichever is the earliest.
and pla-tofo groups. During the 52-week on-treatment period, several occurrences of urinary and genital tract infections were also reported as TEAEs in the tofo-tofo group. Furthermore, improvements in glycaemic control, body weight, FPG, systolic and diastolic blood pressure, uric acid and triglycerides were generally maintained during the study period in the tofo-tofo and pla-tofo groups after tofogliflozin administration. This study has demonstrated the safety and efficacy of tofogliflozin as add-on to insulin therapy in T2DM patients, offering a new therapeutic solution to diabetes management.
Hypoglycaemia was the most common AE in the tofo-tofo group at Week 52 and at Week 16 (30.7% and 42.9%, respectively). Results for each insulin regimen showed that more than 60% of patients who used basal-bolus insulin experienced hypoglycaemia. Compared with other OADs in general, the SGLT2 inhibitor class causes hypoglycaemia less frequently because of its insulin-independent mechanism, which reduces renal glucose reabsorption. 9 Previous studies have found increased frequencies of hypoglycaemia (35.0%-59.0%) when SGLT2 inhibitors were added to insulin, [10] [11] [12] and those proportions were generally consistent with those of our study. Thus, clinicians should pay careful attention to hypoglycaemia, especially when proceeding with combination treatment with basal-bolus insulin and tofogliflozin.
Urinary tract and genital infections, the most common AEs of SGLT2 inhibitors, 13 appeared in a small number of patients (< 3%) throughout this study. Similar frequencies were reported in a previous study of 52-week tofogliflozin monotherapy, with groups receiving 20 and 40 mg tofogliflozin (1.6% and 0.8% for urinary tract infection, 0% and 1.6% for genital infection, 4.7% and 2.4% for cystitis, respectively). 3 In this study, only 5 patients discontinued treatment in the tofo-tofo group, including 1 patient who discontinued because of genital infection.
Other AEs, such as those related to volume depletion and excessive urination, have been observed in other studies of SGLT2 inhibitors added to insulin. 11, 12, 14, 15 These AEs appeared also in our study. Although the typical AEs of SGLT2 inhibitors should be borne in mind, few serious AEs led to treatment discontinuation and no death was observed in the tofo-tofo group, which indicates that tofogliflozin is well tolerated and the continuous use of tofogliflozin addon to insulin therapy may be a safe option for T2DM patients.
Ketoacidosis has been a controversial topic concerning use of an SGLT2 inhibitor because of the risk of ketoacidosis that is potentially induced by SGLT2 inhibitors [16] [17] [18] [19] [20] and the related warning issued by the US Food and Drug Administration (FDA). 21, 22 In this study, the ketone increase in blood and the ketone presence in urine were observed in both treatment groups, although no patients were diagnosed with diabetic ketoacidosis. Given that the risk of ketoacidosis may be a class effect, which was suggested by previous studies, and that ketones were observed in this study, continuous investigations concerning ketoacidosis and use of SGLT2 inhibitors, including tofogliflozin, should be explored further. Patients who received tofogliflozin in both the double-blind and extension phases were referred to as the 'tofo-tofo group', and patients who received placebo in the double-blind phase and tofogliflozin in the extension phase were referred to as the 'pla-tofo group'. The graph includes data obtained from the first dose of tofogliflozin or placebo during the entire treatment period or up to the introduction of rescue medication, 1 day after the last dose of tofogliflozin or placebo, whichever is the earliest.
Values are given as mean (%) AE standard error. Abbreviations: HbA1c, glycosylated haemoglobin; mITT, modified intention-to-treat; SE, standard error
In terms of efficacy, we observed reduced levels of HbA1c, FPG, systolic and diastolic blood pressure, uric acid and triglycerides that were sustained throughout the study period in the tofo-tofo group.
We also observed these reductions in the pla-tofo group after initiating tofogliflozin administration. Overall, the effect of tofogliflozin add-on to insulin therapy was favourable, and mostly consistent with previous long-term studies on other SGLT2 inhibitors added to insulin. [10] [11] [12] In line with previous studies on long-term SGLT2 inhibitors added to insulin treatment, a subtle reduction in insulin was observed in this study. 12, 24, 25 The rather small improvement in glucose observed in this study may explain the slight reduction in insulin, as the majority presumably did not require insulin reduction (HbA1c responder rates <7.0% and ≤6.5% at Week 52, 15.0% and 3.6%, respectively, in the tofo-tofo group). Additionally, the titration algorithm was not specified in the protocol, and changing the insulin dose was at the discretion of the investigator. Those factors may also have played a role in the subtle reduction in insulin observed in this study. These results suggest the importance of insulin adjustment that is appropriate for individuals, to ultimately achieve good glycaemic control and to prevent further comorbidities. Patients who received tofogliflozin in both the double-blind and extension phases were referred to as the 'tofo-tofo group', and patients who received placebo in the double-blind phase and tofogliflozin in the extension phase were referred to as the 'pla-tofo group'. (A-B) mean AE SE of FPG and insulin dose. (C) mean change AE SE in body weight. The graph includes data obtained from the first dose of tofogliflozin or placebo during the entire treatment period or up to introduction of the rescue medication, 1 day after the last dose of the tofogliflozin or placebo, whichever is the earliest. Abbreviations: FPG, fasting plasma glucose; mITT, modified intention-to-treat; SE, standard error SGLT2 inhibitors, when used as monotherapy, or in combination therapy with OADs or insulin, have been shown to elevate LDL cholesterol. 12, [26] [27] [28] [29] [30] [31] Likewise, in our study, LDL cholesterol levels were elevated, in both the tofo-tofo and pla-tofo groups, suggesting that it may be a class effect. The mechanisms of increase in LDL cholesterol with SGLT2 inhibitors are yet to be revealed, warranting further investigation.
Tofogliflozin add-on to insulin therapy also reduced weight and has been demonstrated in studies of tofogliflozin and other SGLT2
inhibitors as add-on to insulin therapy for both short and long terms. 3, 4, 10, 14, 15 A study of dapagliflozin, a class of SGLT2 inhibitors, that measured body composition found that most weight reduction occurred by fat loss and that urinary glucose excretion was associated with weight reduction. 32 Another study of tofogliflozin added to insulin also reported significant decreases in body fat but not in skeletal muscle mass or body fluid after 12 weeks of treatment, implying that weight reduction may have been attributable to fat loss. 33 These results suggest that the continuous weight-reduction effect of tofogliflozin in this study may be explained also by fat loss.
Weight gain may worsen insulin resistance, 34 which may necessitate higher doses of insulin. In addition, another study showed that each −1% reduction in HbA1c achieved with insulin was estimated to have an association of an approximate 2-kg increase in weight during a 1-year period of therapy. 35 Under such circumstances, the effect of weight reduction with tofogliflozin plays a prominent role in combination therapy with insulin, especially for patients who require weight control.
The findings of this study require some careful considerations.
First, the conclusion may be limited to the population studied and may not be entirely applicable to a worldwide T2DM general population. Second, the change in insulin dose was at the investigator's discretion during the extension phase. Thus, we cannot evaluate the full effect of tofogliflozin on changed insulin doses. Third, baseline characteristics between groups differed in terms of age, BMI and duration of diabetes. Finally, we collected the frequencies of AEs via patient diaries and telephone interviews, which mainly relied on patient discretion, and may have over or under estimated the frequencies of AEs.
In conclusion, tofogliflozin add-on to insulin treatment induces some AEs typical of the SGLT2 inhibitor class, such as AEs related to volume depletion, excessive urination and genital and urinary tract infections. However, tofogliflozin is generally well tolerated. Furthermore, improved glycaemic control and reduced weight are well sustained for T2DM patients. This study demonstrates the safety and efficacy of tofogliflozin as add-on to insulin therapy in T2DM patients, offering a new therapeutic solution to diabetes management.
